![]() Most patients - 77% - received at least 1 prior life-prolonging therapy such as enzalutamide (Xtandi 48%), abiraterone (Zytiga 45%), cabazitaxel (6%), docetaxel (25%) or sipuleucel-T Provenge (Provenge 24%). Between 5 and 6 injections of radium-223 were received by 69% of patients. In the analysis, 81% of patients had bone metastases only. ![]() Researchers included 498 patients, with a median age of 74 years in this analysis who were enrolled in the REASSURE study from 2014 to 2017. In addition, researchers also monitored for patient-reported pain. Researchers primarily focused on short- and long-term safety including second primary malignancies and the incidence of bone marrow suppression. In this analysis, researchers focused on patients with confirmed metastatic castration-resistant prostate cancer from the United States who were scheduled to receive treatment with radium-223. Song, MD, co-director of the prostate cancer multidisciplinary clinic and professor of radiation oncology and molecular radiation sciences at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, said during the poster presentation. “Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” Daniel Y. In addition, treatment with radium-223 resulted in overall survival (OS) of approximately 18 months in patients with metastatic castration-resistant prostate cancer. Results from the REASSURE study (NCT02141438) analyzing radium-223 in patients with metastatic castration-resistant prostate cancer was safe and effective, and did not hinder subsequent treatments.įindings from the study, which were presented at the 2023 American Society of Clinical Oncology (ASCO) ASCO Annual Meeting, demonstrated that most patients completed five to six injections of radium-223 and no new safety signals were observed.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |